What is Lumeda?
Lumeda is a pioneering company focused on the therapeutic application of advanced photonics and proprietary software to enhance the efficacy and accessibility of photodynamic therapy (PDT). The company's core innovation lies in automating and digitizing PDT light delivery, aiming to improve treatment planning and patient outcomes for conditions such as non-small cell lung cancer (NSCLC) and other thoracic malignancies. Lumeda's multidisciplinary team possesses extensive experience in the photonics industry, coupled with a strong track record in systems engineering and the commercialization of novel technologies.
How much funding has Lumeda raised?
Lumeda has raised a total of $4.3M across 1 funding round:
Series A
$4.3M
Series A (2021): $4.3M with participation from Cycle Venture Partners and Connecticut Innovations
Key Investors in Lumeda
Cycle Venture Partners
Cycle Venture Partners is an investment entity that has participated in Lumeda's funding rounds, contributing to the company's capital growth.
Connecticut Innovations
Connecticut Innovations (ctinnovations.com) is Connecticuts strategic venture capital arm and quasipublic investment agency, providing equity and debt financing, strategic guidance, and connections to help innovative, growing companies in the state scale, with dedicated funds for sectors like AI/quantum, climate tech, and biosciences.
What's next for Lumeda?
The recent major strategic investment positions Lumeda for accelerated growth and further development of its innovative PDT platform. This capital infusion is expected to fuel advancements in clinical applications, expand market reach, and solidify Lumeda's commitment to pioneering the utility of PDT for improved patient care in oncology. The company's focus on automating light delivery suggests a strategic move towards making complex treatments more standardized and accessible.
See full Lumeda company page
